Jonathan S Duke-Cohan

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Genetic fixity in the human major histocompatibility complex and block size diversity in the class I region including HLA-E
    Viviana Romero
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA, USA
    BMC Genet 8:14. 2007
  2. pmc Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?
    Aleksi Sedo
    Laboratory of Cancer Cell Biology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
    Arthritis Res Ther 7:253-69. 2005
  3. ncbi request reprint Attractin: cautionary tales for therapeutic intervention in molecules with pleiotropic functionality
    Jonathan S Duke-Cohan
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Environ Pathol Toxicol Oncol 23:1-11. 2004
  4. ncbi request reprint Regulation and function of SKAP-55 non-canonical motif binding to the SH3c domain of adhesion and degranulation-promoting adaptor protein
    Jonathan S Duke-Cohan
    Department of Medical Oncology and Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Biol Chem 281:13743-50. 2006
  5. pmc The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays
    Jonathan S Duke-Cohan
    Laboratory of Immunobiology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Vaccine 27:1154-65. 2009
  6. pmc Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration
    Marissa B Wilck
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Infect Dis 201:1361-70. 2010
  7. pmc Dynamic control of β1 integrin adhesion by the plexinD1-sema3E axis
    Young I Choi
    Laboratory of Immunobiology and Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115
    Proc Natl Acad Sci U S A 111:379-84. 2014
  8. pmc Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax
    Michael S Seaman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Infect Dis 201:1353-60. 2010
  9. pmc RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
    Yanping Xiao
    Department of Medical Oncology, Dana Farber Cancer Institute 2 Division of Immunology and Department of Pediatrics, Boston Children s Hospital 3 Department of Microbiology and Immunobiology and 4 Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115
    J Exp Med 211:943-59. 2014
  10. pmc PlexinD1 glycoprotein controls migration of positively selected thymocytes into the medulla
    Young I Choi
    Laboratory of Immunobiology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Immunity 29:888-98. 2008

Collaborators

  • E J Yunis
  • Wei Chen
  • Dale T Umetsu
  • Sanhong Yu
  • Arlene H Sharpe
  • Katharina Gaus
  • Jerome Ritz
  • Christopher E Rudd
  • Vladimir Brusic
  • Fanny Mann
  • Michael S Seaman
  • Edward Alan Fox
  • C A Alper
  • BARBARA BREGMAN
  • Aleksi Sedo
  • Young I Choi
  • Yanping Xiao
  • Ellis L Reinherz
  • Marissa B Wilck
  • Ovidiu Marina
  • Rosalia Rabinovsky
  • Abdallah Azouz
  • Viviana Romero
  • Fatima W Khwaja
  • Simone Di Giovanni
  • Ping Hua
  • Thibault Tabarin
  • Gordon J Freeman
  • Baogong Zhu
  • Wen Tang
  • Denis Bedoret
  • Rosemarie H DeKruyff
  • Jérémie Rossy
  • Xia Bu
  • Baoyu Liu
  • Jingang Gui
  • Loise M Francisco
  • Lining Ju
  • Cheng Zhu
  • Melinda A Biernacki
  • Haesook T Kim
  • Kristen E Stevenson
  • Catherine J Wu
  • Christine M Canning
  • Raphael Dolin
  • Ayush Giri
  • Stephen R Walsh
  • Colleen Devoy
  • Robert J Soiffer
  • Edwin P Alyea
  • Jane A Kleinjan
  • Jeffery L Kutok
  • Lindsey R Baden
  • Lizanne C Noble
  • Ursula Hainz
  • Ann Cai
  • Wandi Zhang
  • Donna Neuberg
  • Lauren E Grandpre
  • Fenglong Liu
  • Panisa Pochanard
  • Chontelle McNear
  • Levi A Garraway
  • Saskia M Brachmann
  • William R Sellers
  • Maris A Handley
  • Wesam B Ahmed
  • Linda K Clayton
  • Jonathan A Epstein
  • Dolores A Fici
  • Tatiana Romero
  • Joaquin Zuniga
  • Zaheed Husain
  • Lama El-Dahdah
  • Ingrid Almeciga
  • Olga P Clavijo
  • Teresa M Gunn
  • Charles E Larsen
  • Zuheir L Awdeh
  • Dennis R Alford
  • Erwin G Van Meir
  • Daniel J Brat
  • Melissa Thouin
  • Tom Finn
  • Eric P Hoffman
  • Alan I Faden
  • Susan Knoblach
  • Alexander Yakovlev
  • Andrea De Biase

Detail Information

Publications16

  1. pmc Genetic fixity in the human major histocompatibility complex and block size diversity in the class I region including HLA-E
    Viviana Romero
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA, USA
    BMC Genet 8:14. 2007
    ..The definition of human MHC class I haplotypes through association of HLA-A, HLA-Cw and HLA-B has been used to analyze ethnicity, population migrations and disease association...
  2. pmc Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?
    Aleksi Sedo
    Laboratory of Cancer Cell Biology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
    Arthritis Res Ther 7:253-69. 2005
    ..The differing specific activities of the DPPIV family members and their differential inhibitor response provide new insights into therapeutic design...
  3. ncbi request reprint Attractin: cautionary tales for therapeutic intervention in molecules with pleiotropic functionality
    Jonathan S Duke-Cohan
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Environ Pathol Toxicol Oncol 23:1-11. 2004
    ....
  4. ncbi request reprint Regulation and function of SKAP-55 non-canonical motif binding to the SH3c domain of adhesion and degranulation-promoting adaptor protein
    Jonathan S Duke-Cohan
    Department of Medical Oncology and Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Biol Chem 281:13743-50. 2006
    ..Our findings identify a RKXXY294 motif in SKAP-55 that mediates unique ADAP SH3c domain binding and is needed for LFA-1-mediated adhesion and cytokine production...
  5. pmc The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays
    Jonathan S Duke-Cohan
    Laboratory of Immunobiology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Vaccine 27:1154-65. 2009
    ..Our findings have important implications both for design of new recombinant subunit vaccines as well as for methods of assaying the human antibody response utilizing recombinant proteins produced in vitro...
  6. pmc Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration
    Marissa B Wilck
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Infect Dis 201:1361-70. 2010
    ..We conducted a clinical trial of the safety and immunogenicity of modified vaccinia Ankara (MVA) to examine the effects of dose and route of administration...
  7. pmc Dynamic control of β1 integrin adhesion by the plexinD1-sema3E axis
    Young I Choi
    Laboratory of Immunobiology and Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115
    Proc Natl Acad Sci U S A 111:379-84. 2014
    ..Our results demonstrate plexin-tunable molecular features of integrin adhesion with broad implications for many cellular processes. ..
  8. pmc Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax
    Michael S Seaman
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    J Infect Dis 201:1353-60. 2010
    ..To investigate this question, we examined the effect of immunization with modified vaccinia Ankara (MVA) on subsequent challenge with replication-competent vaccinia virus (Dryvax)...
  9. pmc RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
    Yanping Xiao
    Department of Medical Oncology, Dana Farber Cancer Institute 2 Division of Immunology and Department of Pediatrics, Boston Children s Hospital 3 Department of Microbiology and Immunobiology and 4 Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115
    J Exp Med 211:943-59. 2014
    ..Understanding this pathway may provide insights into how to optimally modulate the PD-1 pathway in cancer immunotherapy while minimizing adverse events. ..
  10. pmc PlexinD1 glycoprotein controls migration of positively selected thymocytes into the medulla
    Young I Choi
    Laboratory of Immunobiology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Immunity 29:888-98. 2008
    ..These results demonstrate the importance of plexinD1 in directing migration of maturing thymocytes via modulation of biological responses to chemokine gradients...
  11. ncbi request reprint Juvenile-onset loss of lipid-raft domains in attractin-deficient mice
    Abdallah Azouz
    Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Exp Cell Res 313:761-71. 2007
    ....
  12. pmc p85 Associates with unphosphorylated PTEN and the PTEN-associated complex
    Rosalia Rabinovsky
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Mol Cell Biol 29:5377-88. 2009
    ..Together, these results suggest that integration of p85 into the PAC may provide a novel means of downregulating the PI3K/AKT pathway...
  13. pmc Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens
    Ovidiu Marina
    Cancer Vaccine Center and Departments of Medical Oncology and Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 70:1344-55. 2010
    ..Moreover, antibody reactivity against these antigens was temporally correlated with clinical disease regression. These B-cell antigens represent promising biomarkers of effective anti-CLL immunity...
  14. ncbi request reprint Human secreted attractin disrupts neurite formation in differentiating cortical neural cells in vitro
    Wen Tang
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neuropathol Exp Neurol 61:767-77. 2002
    ....
  15. ncbi request reprint Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration
    Fatima W Khwaja
    Laboratory of Molecular Neuro Oncology, Department of Neurosurgery, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 12:6331-6. 2006
    ..The goal of our study was to find reliable markers that could be used for disease monitoring as well as to identify new targets for the therapeutic intervention for malignant astrocytoma (WHO grades 3 and 4)...
  16. ncbi request reprint Neuronal plasticity after spinal cord injury: identification of a gene cluster driving neurite outgrowth
    Simone Di Giovanni
    Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA
    FASEB J 19:153-4. 2005
    ..Finally, in vitro transfection experiments in primary dorsal root ganglion cells showed that cluster members act synergistically to drive neurite outgrowth...